Investing.com - Financial Markets Worldwide

SpringWorks Therapeutics Inc (SWTX)

NASDAQ
Currency in USD
46.99
+0.01(+0.02%)
Closed·
Showing SpringWorks historical data. For real-time data please try another search
Fair Value
Unlock Value
Day's Range
46.9847.01
52 wk Range
28.2162.00
Key Statistics
Edit
Prev. Close
46.99
Open
46.99
Day's Range
46.98-47.01
52 wk Range
28.21-62
Volume
5.01M
Average Volume (3m)
5.85M
1-Year Change
40.56%
Book Value / Share
5.57
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SWTX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Strong Buy
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.
Unlock InvestingPro

SpringWorks Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

SpringWorks Therapeutics Inc Company Profile

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. It offers OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor for the treatment of desmoid tumors; and GOMEKLI (mirdametinib), an oral small molecule inhibitor of MEK1 and MEK2 for the treatment of adult and pediatric patients two years of age and older with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). The company also develops Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer; and mirdametinib for the treatment of solid tumors harboring other MAPK aberrations, including for the treatment of pediatric and young adult patients with low-grade gliomas that is in Phase 1/2 clinical trial. In addition, its products under development include Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has license agreements with Pfizer Inc. for nirogacestat and mirdametinib; and Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut. As of July 1, 2025, SpringWorks Therapeutics, Inc. operates as a subsidiary of Merck KGaA.

Industry
Pharmaceuticals
Sector
Healthcare
Employees
368
Market
United States

SpringWorks Therapeutics Inc SWOT Analysis

Acquisition Impact
Explore how Merck KGaA's $3.9 billion acquisition of SpringWorks Therapeutics could reshape the company's future and accelerate its growth in rare diseases
Pipeline Potential
Delve into SpringWorks' promising therapies, including Ogsiveo and Gomekli, and their market opportunities in desmoid tumors and neurofibromatosis
Financial Outlook
Analysts project continued negative earnings despite strong sales growth, with EPS estimates ranging from -$3.26 to -$1.94 for upcoming fiscal years
Market Positioning
Learn how SpringWorks navigates the competitive biotech landscape, awaits EU regulatory decisions, and leverages its expertise in rare diseases and oncology
Read full SWOT analysis

Compare SWTX to Peers and Sector

Metrics to compare
SWTX
Peers
Sector
Relationship
P/E Ratio
−13.9x0.0x−0.5x
PEG Ratio
−0.420.000.00
Price/Book
8.5x0.0x2.6x
Price / LTM Sales
16.1x0.0x3.3x
Upside (Analyst Target)
0.0%0.0%43.5%
Fair Value Upside
Unlock0.0%6.3%Unlock

Earnings

Latest Release
Jul 30, 2025
EPS / Forecast
-- / -0.7441
Revenue / Forecast
-- / 73.21M
EPS Revisions
a
a
Unlock
Last 90 days

SWTX Income Statement

People Also Watch

YPF Sociedad Anonima
35.100
YPF
+4.84%
Insmed
111.62
INSM
+0.34%
Verona Pharma ADR
105.380
VRNA
-0.09%
Daktronics
16.830
DAKT
+0.84%
Banco Macro B ADR
72.84
BMA
+4.96%
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.